Details for Patent: 10,512,657
✉ Email this page to a colleague
Which drugs does patent 10,512,657 protect, and when does it expire?
Patent 10,512,657 protects LIVMARLI and is included in one NDA.
This patent has seventy-six patent family members in twenty-two countries.
Summary for Patent: 10,512,657
| Title: | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| Abstract: | Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Gedulin Bronislava, Grey Michael, "ODonnell Niall" |
| Assignee: | LUMENA PHARMACEUTIALS LLC |
| Application Number: | US15137323 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,512,657
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTATIS (PFIC) | ⤷ Sign Up | ||||
| Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-002 | Jul 24, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,512,657
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2771003 | ⤷ Sign Up | 2023C/521 | Belgium | ⤷ Sign Up |
| European Patent Office | 2771003 | ⤷ Sign Up | 301234 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2771003 | ⤷ Sign Up | CA 2023 00017 | Denmark | ⤷ Sign Up |
| European Patent Office | 2771003 | ⤷ Sign Up | 122023000029 | Germany | ⤷ Sign Up |
| European Patent Office | 2771003 | ⤷ Sign Up | 21/2023 | Austria | ⤷ Sign Up |
| European Patent Office | 2771003 | ⤷ Sign Up | CR 2023 00017 | Denmark | ⤷ Sign Up |
| European Patent Office | 2771003 | ⤷ Sign Up | 2390017-8 | Sweden | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
